Day One Biopharma Files 8-K: Material Agreement & Equity Sales
Ticker: DAWN · Form: 8-K · Filed: Jul 25, 2024 · CIK: 1845337
Sentiment: neutral
Topics: material-agreement, equity-sale, disclosure
TL;DR
Day One Biopharma inked a material deal and sold some equity. Details in the 8-K.
AI Summary
On July 23, 2024, Day One Biopharmaceuticals, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Registrant
- July 23, 2024 (date) — Date of earliest event reported
- 2000 Sierra Point Parkway, Suite 501 (address) — Principal executive offices
- Brisbane, California (location) — Principal executive offices location
- 94005 (zip_code) — Principal executive offices zip code
FAQ
What is the nature of the material definitive agreement entered into by Day One Biopharmaceuticals, Inc. on July 23, 2024?
The filing states that Day One Biopharmaceuticals, Inc. entered into a material definitive agreement on July 23, 2024, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales disclosed in the 8-K?
The filing mentions 'Unregistered Sales of Equity Securities' but does not specify the type or amount of equity securities sold.
What is the primary business of Day One Biopharmaceuticals, Inc. according to the SIC code?
According to the Standard Industrial Classification (SIC) code provided, Day One Biopharmaceuticals, Inc. is in the business of 'PHARMACEUTICAL PREPARATIONS [2834]'.
When was Day One Biopharmaceuticals, Inc. incorporated or jurisdiction of incorporation?
Day One Biopharmaceuticals, Inc. is incorporated in Delaware.
What is the Commission File Number for Day One Biopharmaceuticals, Inc.?
The Commission File Number for Day One Biopharmaceuticals, Inc. is 001-40431.
Filing Stats: 1,044 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-07-25 06:04:59
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share DAWN Nasdaq Global Select
- $71 million — ense fee in the amount of approximately $71 million within thirty days after the effective
- $40 m — tock (the "Company Share Issuance") for $40 million, at a price per share representin
- $350 million — eligible to receive up to approximately $350 million in additional launch and sales mileston
Filing Documents
- d860436d8k.htm (8-K) — 29KB
- d860436dex991.htm (EX-99.1) — 34KB
- g860436g04j44.jpg (GRAPHIC) — 17KB
- 0001193125-24-184249.txt ( ) — 219KB
- dawn-20240723.xsd (EX-101.SCH) — 3KB
- dawn-20240723_lab.xml (EX-101.LAB) — 18KB
- dawn-20240723_pre.xml (EX-101.PRE) — 11KB
- d860436d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, regarding the License Agreement, dated July 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: July 25, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer